Back to search

Article

Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in <i>Mycobacterium tuberculosis</i>

2018-10-31

Abstract excerpt

Delamanid represents one of two novel antimicrobial classes approved to treat tuberculosis in over 40 years. Pretomanid is another promising nitroimidazole pro-drug in clinical development. Characterization of the full spectrum of mutations conferring resistance to nitroimidazoles and their related phenotypes in Mycobacterium tuberculosis will inform development of suitable genotypic and phenotypic drug susceptib...

Identifiers and source

Literature Corpus work
4c24e939-0405-5235-bc36-dcc40279cfcb
DOI
10.1101/457754
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in <i>Mycobacterium tuberculosis</i>DOI 10.1101/457754
Select a neighboring publication to make it the new centre.